In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk AS

www.novonordisk.com

Latest From Novo Nordisk AS

Roche Takes Orphan Satralizumab To EMA

There are six new entries on the latest list of products under review at the European Medicines Agency – products with orphan status from Roche and Novo Nordisk and four generic or biosimilars.

Europe Drug Review

Sanofi's New CEO Paul Hudson Poised To Write The Next Chapter

Less than one month into the job, Sanofi CEO Paul Hudson talked about his early perspective on how he can build on Sanofi's strengths and deliver needed changes.

Leadership Companies

Keeping Track: Intercept Submits OCA For NASH; Zogenix’ Fintepla Returns; US FDA Approves Bavarian Nordic Vaccine

The latest drug development news and highlights from our US FDA Performance Tracker

US FDA Performance Tracker Drug Review

Countdown To Transition: US FDA Says 91 Drugs Will Become Biologics In March 2020

A Pink Sheet infographic shows how insulins account for the largest category of transition products, with 27 NDAs that will be "deemed" BLAs in six months; agency is working on a policy to address the transition of authorized generic insulins to regulation under the PHS Act, Office of Therapeutic Biologics And Biosimilars acting policy director Eva Temkin says.

Biosimilars Biologics
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register